Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial reduction in tumor recurrence, progression, or death compared with standard chemotherapy. Data also pointed to a consistent safety profile for the combination regimen. The companies signaled that regulatory filings based on these results are expected. For you as an investor, this update sits at the heart of Pfizer's focus on oncology, which is one of its key areas alongside vaccines and other specialty medicines. Bladder cancer is a complex disease area with significant unmet medical need, so any treatment option that compares favorably with chemotherapy tends to draw close attention from both clinicians and markets.
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit [Yahoo! Finance]Yahoo! Finance
- A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge [Yahoo! Finance]Yahoo! Finance
- Pfizer: Obesity Hype And Vaccine Policy Shocks [Seeking Alpha]Seeking Alpha
- Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline [Yahoo! Finance]Yahoo! Finance
- Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/3/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- PFE's page on the SEC website